share_log

Supernus Pharmaceuticals Announces Interim Analysis Data From Phase 2a Clinical Study Of SPN-817 For Treatment-Resistant Seizures

Benzinga ·  May 24 04:09
Supernus Pharmaceuticals Announces Interim Analysis Data From Phase 2a Clinical Study Of SPN-817 For Treatment-Resistant Seizures
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment